Prevention of accelerated cell aging in the Werner syndrome.

Abstract

In the Werner syndrome (WS) fibroblasts have an increased life span and growth rate when treated with the p38 inhibitor SB203580. Additionally, the cellular morphology reverts to that seen in young normal fibroblasts. The p38 pathway is activated in young WS cells, associated with high levels of p21(WAF1) leading to cell cycle arrest, and is suppressed by SB203580. As these changes are also seen in telomerized WS cells, these data show that the growth problems seen in WS cells, and perhaps the accelerated in vivo aging, are due to a telomere-independent premature senescence mechanism. The suppression of this mechanism by SB203580 treatment suggests a route whereby WS may be amenable to therapeutic intervention.

• Authors: Terence Davis, Michèle F Haughton, Christopher J Jones, David Kipling
• Journal: Annals of the New York Academy of Sciences (Ann N Y Acad Sci) Vol. 1067 Pg. 243-7 (May 2006) ISSN: 0077-8923 [Print] United States
• PMID: 16803993 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Actins
• Cyclin-Dependent Kinase Inhibitor p21
• Enzyme Inhibitors
• Imidazoles
• Pyridines
• Tumor Suppressor Protein p53
• p38 Mitogen-Activated Protein Kinases
• Telomerase
• SB 203580

Topics

• Actins (metabolism)
• Aging, Premature (prevention & control)
• Cells, Cultured
• Cellular Senescence (drug effects, genetics, physiology)
• Cyclin-Dependent Kinase Inhibitor p21 (metabolism)
• Enzyme Inhibitors (pharmacology)
• Fibroblasts (drug effects, metabolism, pathology)
• Humans
• Imidazoles (pharmacology)
• Pyridines (pharmacology)
• Telomerase (genetics, metabolism)
• Telomere (genetics, metabolism)
• Tumor Suppressor Protein p53 (metabolism)
• Werner Syndrome (genetics, pathology)
• p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors)